Condition: Prostate Cancer (Adenocarcinoma) · Sponsor: The Methodist Hospital Research Institute
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
This description comes directly from the study's public registry record.
Vivian MacDonnell, CCRP · 713-441-8113 · vmmacdonnell@houstonmethodist.org
Andrew Fararch, MD · 713-441-4800 · amfarach@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07182279